Veronica Marrella1, Virginia Maina, Anna Villa. 1. Institute of Genetic and Biomedical Research, Milan Unit, National Research Council (CNR), Milan bIstituto Clinico Humanitas IRCCS, Rozzano, Italy.
Abstract
PURPOSE OF REVIEW: During the past decade, easy access to sequence analyses has allowed us to increase our understanding of the pathogenesis of severe combined immunodeficiencies. Here, we describe the expanding clinical and immunological spectrum associated with Omenn syndrome phenotype. In particular, we review the cellular and molecular mechanisms involved in the pathophysiology of 'classical' Omenn syndrome due to the recombination activating gene (RAG) defects and of a new subgroup of Omenn-like disorders. RECENT FINDINGS: Different types of mutations are associated with the Omenn phenotype characterized by skin erythroderma, oligoclonal-activated T cells and elevated IgE in the absence of circulating B cells. Extensive studies conducted over the last few years have allowed the definition of the 'classical form' of Omenn syndrome due to hypomorphic defects in genes involved in V(D)J recombination, mainly RAG genes, and 'Omenn-like' features associated with mutations in genes involved in the maturation steps of lymphoid cells other than V(D)J recombination. Moreover, an increasing number of diseases other than those due to V(D)J recombination defects develop Omenn signs. SUMMARY: Impaired but not abolished V(D)J recombination process leads to the generation of a few T cells which expand in the periphery, infiltrate target organs such as skin and gut, resulting in severe erythroderma and colitis, both typical signs of Omenn syndrome. Extensive molecular studies now demonstrate that genes other than V(D)J molecules have a role in the pathogenesis of this disease, supporting the evidence that 'Omenn' defines an inflammatory condition associated with various genetic defects.
PURPOSE OF REVIEW: During the past decade, easy access to sequence analyses has allowed us to increase our understanding of the pathogenesis of severe combined immunodeficiencies. Here, we describe the expanding clinical and immunological spectrum associated with Omenn syndrome phenotype. In particular, we review the cellular and molecular mechanisms involved in the pathophysiology of 'classical' Omenn syndrome due to the recombination activating gene (RAG) defects and of a new subgroup of Omenn-like disorders. RECENT FINDINGS: Different types of mutations are associated with the Omenn phenotype characterized by skin erythroderma, oligoclonal-activated T cells and elevated IgE in the absence of circulating B cells. Extensive studies conducted over the last few years have allowed the definition of the 'classical form' of Omenn syndrome due to hypomorphic defects in genes involved in V(D)J recombination, mainly RAG genes, and 'Omenn-like' features associated with mutations in genes involved in the maturation steps of lymphoid cells other than V(D)J recombination. Moreover, an increasing number of diseases other than those due to V(D)J recombination defects develop Omenn signs. SUMMARY: Impaired but not abolished V(D)J recombination process leads to the generation of a few T cells which expand in the periphery, infiltrate target organs such as skin and gut, resulting in severe erythroderma and colitis, both typical signs of Omenn syndrome. Extensive molecular studies now demonstrate that genes other than V(D)J molecules have a role in the pathogenesis of this disease, supporting the evidence that 'Omenn' defines an inflammatory condition associated with various genetic defects.
Authors: Xiaomin Yu; Jorge R Almeida; Sam Darko; Mirjam van der Burg; Suk See DeRavin; Harry Malech; Andrew Gennery; Ivan Chinn; Mary Louise Markert; Daniel C Douek; Joshua D Milner Journal: J Allergy Clin Immunol Date: 2014-01-07 Impact factor: 10.793
Authors: Sebastian Fuchs; Anne Rensing-Ehl; Ulrich Pannicke; Myriam R Lorenz; Paul Fisch; Yogesh Jeelall; Jan Rohr; Carsten Speckmann; Thomas Vraetz; Susan Farmand; Annette Schmitt-Graeff; Marcus Krüger; Brigitte Strahm; Philipp Henneke; Anselm Enders; Keisuke Horikawa; Christopher Goodnow; Klaus Schwarz; Stephan Ehl Journal: Blood Date: 2015-08-19 Impact factor: 22.113
Authors: Adam G W Matthews; Christine E Briggs; Keiichi Yamanaka; Trudy N Small; Jana L Mooster; Francisco A Bonilla; Marjorie A Oettinger; Manish J Butte Journal: PLoS One Date: 2015-04-07 Impact factor: 3.240
Authors: Rosita Rigoni; Elena Fontana; Simone Guglielmetti; Bruno Fosso; Anna Maria D'Erchia; Virginia Maina; Valentina Taverniti; Maria Carmina Castiello; Stefano Mantero; Giovanni Pacchiana; Silvia Musio; Rosetta Pedotti; Carlo Selmi; J Rodrigo Mora; Graziano Pesole; Paolo Vezzoni; Pietro Luigi Poliani; Fabio Grassi; Anna Villa; Barbara Cassani Journal: J Exp Med Date: 2016-02-29 Impact factor: 14.307